Teva Pharmaceutical (TEVA) stock witnessed a significant pre-market plunge of 7.80% on Wednesday, following the company's disappointing Q4 earnings report and weak 2025 guidance.
The drug maker reported Q4 non-GAAP earnings of $0.71 per diluted share, lower than the $1.00 reported in the same quarter last year. While the earnings met analysts' expectations, the company's net revenue for the quarter declined to $4.23 billion from $4.46 billion a year earlier, missing the analysts' forecast of $4.15 billion.
Furthermore, Teva's 2025 outlook dampened investor sentiment. The company expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion, falling short of analysts' estimates of non-GAAP EPS of $2.96 on revenue of $17.09 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。